New hope for adults with stubborn leukemia: blinatumomab shows promise in french study
NCT ID NCT03751072
First seen Mar 23, 2026 · Last updated May 14, 2026 · Updated 9 times
Summary
This study looked at how well a drug called blinatumomab works in 92 adults with B-cell acute lymphoblastic leukemia (ALL) that either came back or didn't respond to treatment. The drug helps the body's immune cells attack leukemia cells. Researchers measured how long patients lived and how many had their cancer shrink or disappear. The study used data from a French program that gave early access to the drug before it was officially approved.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA, IN RELAPSE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CABANNES-HAMY Aurélie
Paris, 75010, France
Conditions
Explore the condition pages connected to this study.